The Italy Mice Model Market was valued at $31.5 Million in 2025 and projected to reach to $47.1 Million by 2030, representing a compound annual growth rate of 8.4%. Italy's mice model market is poised for sustained expansion through 2030, driven by increased pharmaceutical R&D spending and strengthened academic research capabilities.
Italy's mice model market is valued at $31.5 million in 2025, with projections reaching $47.1 million by 2030, representing a robust 8.4% CAGR driven by increased biomedical research investments.
Italy's strengthening life sciences infrastructure and world-class academic research institutions are catalyzing demand for advanced mice models in pharmaceutical development and preclinical testing.
Italy's strategic position within Europe's biomedical research ecosystem positions it as a key market for mice model suppliers, with growing collaboration between Italian universities and international pharmaceutical companies.
Italian government initiatives supporting life sciences innovation and EU regulatory frameworks are encouraging pharmaceutical companies to establish research operations, boosting demand for specialized mice models.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | SERVICES (Model Type & Service) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 10% from 2025 to 2030 |
| Largest Segment | MODEL TYPE (Model Type & Service) |
| Market Size Base Year (Billions) | ~USD 1.7 (2025) |
| Revenue Forecast (Billions) | ~USD 2.74 (2030) |
| Segments Covered | Model Type & Service, Type, Technology, Application, Therapeutic Area |
5 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| HORIZON DISCOVERY GROUP PLC | United Kingdom | Private Company | Screening,Research Reagents,Diagnostics, |
| LABORATORY CORPORATION OF AMERICA HOLDINGS | United States | Public Company | Routine and wellness diagnostics (chemistry, hematology, urinalysis, wellness programs),Specialty and esoteric testing (gene-based, oncology, infectious disease, women’s health, pharmacogenetics),Biopharma Laboratory Services (clinical trial, central lab, medical device and diagnostic R&D), |
| CHARLES RIVER LABORATORIES | United States | Public Company | Discovery and Safety Assessment,Research Models and Services,Manufacturing Solutions, |
| THE JACKSON LABORATORY | United States | Foundation/Charitable Institution | Mouse breeding and colony management services,Cryopreservation, recovery, and genetic resource management,Phenotyping, efficacy testing, and study-ready induced models, |
| INOTIV | United States | Public Company | Research Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software, |
| JSR CORPORATION | Japan | Private Company | Digital Solutions (lithography, photoresists, packaging, CMP, display materials),Plastics (synthetic resins: ABS, AES, AS, ASA),Life Sciences (diagnostic reagents, bioprocess materials, drug discovery support), |
| BIOCYTOGEN | China | Public Company | Gene-Editing Services,Pharmacological Efficacy & Toxicology Services,Model Animals (Breeding & Sales), |
| SHANGHAI MODEL ORGANISMS CENTER, INC. | China | Public Company | Standard and disease mouse models (including toolbox and disease-specific strains),Customized genetically engineered models (KO, KI, humanized, transgenic),Preclinical services (non-GLP tox, PK, pharmacology/PD, phenotype analysis), |
| TRANS GENIC INC. | Japan | Public Company | Drug Discovery Support (non-clinical, bioequivalence, safety tests),Transgenic Models & Reagents (GM mice, antibodies, proteins, cells),Glycan Synthesis & Sugar Chain Analysis, |
| HARBOUR BIOMED | China | Public Company | Harbour Mice platform licensing and collaborations,Immunology clinical assets (e.g., batoclimab, HBM7020, HBM9378),Oncology clinical assets (e.g., porustobart, solid tumor portfolio), |
| GENOWAY | France | Public Company | Custom KO/KI mouse models,Custom KO/KI rat models,Humanized and immunodeficient rodent models (catalog and custom), |
| GEMPHARMATECH | China | Public Company | Standard GEMM catalog (knockout, conditional, knock-in, point-mutation, transgenic),Custom model generation and tool mice,Preclinical testing services, |
| VIVO BIO TECH LTD. | India | Public Company | In vivo and in vitro toxicity, PK/TK, and pharmacology services,SPF lab animals, rodent breeding, custom models, and lab diets,Genotoxicity screening and analytical services, |
Horizon Discovery Group PLC is a United Kingdom-based private company founded in 2005 with 428 employees. The company operates in the life sciences sector, providing specialized research and development services.
Laboratory Corporation of America Holdings is a major United States public company founded in 1995 with 66,385 employees. It is a leading provider of clinical laboratory services and drug development support.
Charles River Laboratories is a United States public company founded in 1947 with 19,000 employees. The company provides preclinical and clinical laboratory services, research models, and safety assessment services.
The Jackson Laboratory is a United States foundation and charitable institution founded in 1929 with 2,100 employees. It is a premier research institution specializing in mammalian genetics and genomics.
Inotiv is a United States public company founded in 1974 with 1,996 employees. The company provides research models, services, and products for the pharmaceutical and biotechnology industries.
JSR Corporation is a Japan-based private company founded in 1948 with 7,997 employees. The company operates in advanced materials and life sciences sectors.
Biocytogen is a China-based public company founded in 2008 with 1,443 employees. The company specializes in the development of genetically engineered animal models for research and drug development.
Shanghai Model Organisms Center, Inc. is a China-based public company founded in 2000 with 848 employees. The company provides model organism services and products for biomedical research.
Trans Genic Inc. is a Japan-based public company founded in 1998 with 227 employees. The company develops and provides transgenic animal models for research applications.
Harbour Biomed is a China-based public company founded in 2016 with 272 employees. The company focuses on antibody and immunotherapy research and development.
Genoway is a France-based public company founded in 1999 with 157 employees. The company specializes in the generation of genetically modified animal models for research.
GemPharmatech is a China-based public company founded in 2017 with 1,590 employees. The company provides laboratory animal models and related research services.
Vivo Bio Tech Ltd. is an India-based public company founded in 1987 with 174 employees. The company provides contract research services and laboratory animal models for pharmaceutical and biotechnology research.
Italy's mice model market is valued at $31.5 million in 2025 and is expected to grow to $47.1 million by 2030.
Italy's mice model market is growing at a compound annual growth rate (CAGR) of 8.4% from 2025 to 2030.
Italy's pharmaceutical R&D, biotech innovation, academic research institutions, and contract research organizations are the primary drivers of market growth.
Italy maintains a significant position in Europe's preclinical research landscape, supported by strong academic institutions and regulatory frameworks that emphasize ethical research practices.
Italy's adherence to EU directives on animal research, emphasis on the 3Rs principle (replacement, reduction, refinement), and investment in alternative methodologies shape market dynamics.
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global mice model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary research was used primarily to identify & collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include the International Mouse Phenotyping Consortium (IMPC), Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), European Molecular Biology Laboratory−European Bioinformatics Institute (EMBL-EBI), Swiss Laboratory Animal Science Association (SGV), Medical Research Council (MRC), Asian Mouse Mutagenesis Resource Association (AMMRA), Department of Biotechnology (DBT) (India), World Health Organization (WHO), United States Food and Drug Administration (US FDA), Annual Reports, SEC Filings, Investor Presentations, Research Journals, Press Releases, and financial statements. These sources also obtained key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative & quantitative information and assess the prospects of the market. Various primary sources from both the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate & validate the total size of the mice model market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

The total market was split into several segments and subsegments after arriving at the overall market size from the estimation process. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides.
An animal model is a valuable resource in biomedical research, chosen for its ability to replicate certain aspects of biological processes or diseases observed in humans. A mouse model is a genetically engineered or naturally occurring mouse strain used in biomedical research to mimic human diseases or conditions. These models are valuable for their biological similarity to humans, ability to be genetically manipulated, and cost-effectiveness, enabling researchers to study disease mechanisms and test novel drug therapies efficiently. Mice share over 95% of human DNA and are biologically similar to humans, thereby being susceptible to similar diseases due to the genetic build-up.
Full forecast, segment splits, and company analysis for all Mice Model Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report